Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Casa di Cura Dott. Pederzoli
Modality
other_biological
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreas Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clostridium Butyricum Miyairi 588 (this asset) | Casa di Cura Dott. Pederzoli | N/A | D · 30 |
| Anti-Psca Monoclonal Antibody Ags-1C4D4 | Agensys, Inc. | P2 | B |
| Cefoxitin | Memorial Sloan Kettering Cancer Center | P3 | B |
| Olaparib | AstraZeneca | P2 | B |
| nhs7108 | Aimmune Nestlé Health Science US R&D, LLC | P2 | CCC |
| Pancrelipase | Aimmune Nestlé Health Science US R&D, LLC | P2 | CCC |
| Irinotecan | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | CCC |
| Cis-Diamminedichloroplatinum Ii | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | CCC |
| Capecitabine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | CCC |
+7 more in the Pancreas Disorder cohort
Other indications for Clostridium Butyricum Miyairi 588
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 66 |
| Nonpapillary Renal Cell Carcinoma | — | P3 | BB · 66 |
| Sarcomatoid Renal Cell Carcinoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Clostridium Butyricum Miyairi 588 in Pancreas Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clostridium-butyricum-miyairi-588-pancreas-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →